Following this trial, an additional phase II trial enrolled patients with NSCLC into two arms: Arm 1 comprised patients that exhibited a performance status (PS) <2 and had failed <2 cycles with platinum based therapy and arm 2 comprised patients that had undergone <2 cycles of platinum based therapy in combination with an EGFR antagonist. Here, EGFR is linked to non-small cell lung carcinoma.